<SEC-DOCUMENT>0001188112-11-001934.txt : 20110714
<SEC-HEADER>0001188112-11-001934.hdr.sgml : 20110714
<ACCEPTANCE-DATETIME>20110714145844
ACCESSION NUMBER:		0001188112-11-001934
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110708
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110714
DATE AS OF CHANGE:		20110714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APPLIED DNA SCIENCES INC
		CENTRAL INDEX KEY:			0000744452
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				592262718
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	002-90539
		FILM NUMBER:		11967851

	BUSINESS ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790
		BUSINESS PHONE:		631 444 6861

	MAIL ADDRESS:	
		STREET 1:		25 HEALTH SCIENCES DRIVE
		STREET 2:		SUITE 113
		CITY:			STONY BROOK
		STATE:			NY
		ZIP:			11790

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PROHEALTH MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20010504

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DCC ACQUISITION CORP
		DATE OF NAME CHANGE:	19990211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DATALINK CAPITAL CORP/TX/
		DATE OF NAME CHANGE:	19980306
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t71128_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>
<head>
    <title>t71128_8k.htm</title>
    <!-- Licensed to: TrIState Financial -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>





<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">______________________<br>
</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">FORM 8-K</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO SECTION 13 OR 15(d) OF THE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES EXCHANGE ACT OF 1934</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____________________</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of report (Date of earliest event reported): July 8, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Applied DNA Sciences, Inc</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact Name of Registrant as Specified in Charter)</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of Incorporation)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">002-90539</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td valign="top" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">59-2262718</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">25 Health Sciences Drive, Suite 215</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stony Brook, New York 11790</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of Principal Executive Offices) (Zip Code)</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">631-444- 8090</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Not Applicable</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former Name or Former Address, if Changed Since Last Report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">&#168;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 1.01&#160;&#160;Entry into a Material Definitive Agreement</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 8, 2011, Applied DNA Sciences, Inc. (the &#8220;Company&#8221;) entered into an agreement, dated as of July 7, 2011 (the &#8220;Agreement&#8221;) with Disc Graphics Inc., a provider of specialty packaging (&#8220;DG&#8221;).</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under the terms of the Agreement, DG will purchase DNA security markers (&#8220;Markers&#8221;) from the Company to be incorporated into coatings for DG&#8217;s products.&#160;&#160;Additionally, DG will be the Company&#8217;s exclusive distributor in North America of Markers for the folding carton offset print sector and non-exclusive distributor of Markers for pressure sensitive labels. Under the Agreement, the Company is obligated to provide Markers for up to a fixed amount of coatings.<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>The Company received an initial fee upon entering the Agreement, and is entitled to an annual fee for the Markers, as well as fees for any authentication services provided by the Company.&#160;&#160;The initial term of the Agreement is three years and will automatically renew for successive one year periods, unless either party terminates the Agreement by giving written notice to the other party at least ninety (90) days prior to the end of the third year.&#160;&#160;After the initial term, the Company has the right to terminate if DG does not pay the annual fee.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A copy of the press release issued by the Company on July 14, 2011 relating to the Agreement is attached as Exhibit 99.1 and is incorporated herein by reference.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 72pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit 99.1</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Press Release issued by Applied DNA Sciences, Inc. on July 14, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center">- 2 -<br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div style="WIDTH: 100%" align="left">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</div>

<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Applied DNA Sciences, Inc.</font></div>
</td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Registrant)</font></div>
</td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="41%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="41%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: <font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ James A. Hayward&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
</td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">James A. Hayward</font></div>
</td>
</tr><tr>
<td valign="top" width="38%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="41%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date: July 14, 2011</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">- 3 -</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
    <title>ex99-1.htm</title>
    <!-- Licensed to: TrIState Financial -->
    <!-- Document Created using EDGARizerAgent 5.2.3.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>





<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;&#160;&#160;&#160;Exhibit 99.1</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><img src="applied.jpg" alt="">&#160;&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

<div>
<hr style="COLOR: mediumslateblue" align="left" noshade size="2" width="100%">
</div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Applied DNA Sciences and Disc Graphics Sign Agreement to Protect Packaging in North America</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">STONY BROOK, N.Y., July 14, 2011/Marketwire/ - Applied DNA Sciences, Inc. (OTCBB: APDN), a provider of DNA-based security solutions, and Disc Graphics announce the signing of an exclusive distribution agreement.&#160;&#160;Disc Graphics (DISC) , a leading source of specialty packaging solutions for more than 40 years, has been granted rights to distribute a unique DNA marker exclusively for the folding carton offset print sector and non-exclusively for pressure sensitive labels in North America. APDN received an initial payment from Disc Graphics and would receive minimum payments annually to maintain exclusivity.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Unique Taggants</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Disc Graphics is using unique DNA taggants, developed specifically for them by APDN, in its labels and packaging business. Disc Graphics is well known in the industry for creating custom solutions to address their customers&#8217; needs and the use of DNA taggants offers a forensic package which will differentiate their product from competitors.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Disc Graphics has a dedicated sales force, which will be trained by APDN, with extensive selling experience to promote this technology. This represents APDN&#8217;s first entry into the packaging market, with an initiative of potentially enormous scale.&#160;&#160;APDN is prepared to fulfill all needs, even as it grows in many other market verticals simultaneously.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Counterfeit Packaging</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The scourge of counterfeiting in packaging has greatly intensified in recent years.&#160;&#160;Counterfeiting has spiked, causing detrimental health concerns for consumers, safety concerns for law enforcement agencies, and financial concerns for businesses worldwide.&#160;&#160;As a result, the global anti counterfeit packaging market will reach about $82.2 billion by the year 2015, according to California-based Global Industry Analysts Inc.,</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">DNA taggants are the most advanced and secure technology available to the printing and packaging industries to combat counterfeit products. APDN&#8217;s SigNature&#174; DNA taggants offer a high level of security and flexibility in a cost-effective and easy-to-use format to suit the requirements and budget of any company.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;This agreement leverages DISC&#8217;s broad customer base of high value brands and offers us a leading edge, forensic anti-counterfeit solution to combat the growing problem of counterfeit and grey market goods entering the supply and distribution chain,&#8221; commented Margaret Krumholz, President of DISC. &#8220;Packaging is on the front line of fighting counterfeiters and we are excited to make DNA an integral part of our overarching package security program. Our core customers including major film studios, pharmaceutical manufacturers, fragrance and luxury brand companies all experience market erosion from counterfeit products and are searching for weapons to battle this multi-billion dollar problem&#8221;.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: gainsboro" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Aside from the loss of revenue, one of the major issues with counterfeits is that while they might look identical, if the counterfeiter has used an inferior grade of material and the product fails, the perception of poor quality falls back on the original manufacturer. Steps are being taken at all stages of the manufacturing and distribution process to address the counterfeiting scourge.</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;APDN can provide the means necessary to authenticate packaging and labels on all products including pharmaceuticals where a counterfeit product can cause illness or even death. Working with DISC will provide APDN with an introduction to brands and companies, expanding the exposure and market reach of the company. We are excited to share our technology with this market leader and believe that this will open up additional markets and customers for both companies,&#8221; commented Dr. James Hayward, APDN President and CEO.</font><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About DISC</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">DISC is a leading producer of packaging and print for the entertainment media, beauty, healthcare, private label and consumer products industries. Headquartered in Hauppauge, New York, DISC is a privately held company whose manufacturing facilities in California, New Jersey and New York adhere to strict ISO 9001:2008 and FDA cGMP standards. FSC Chain-of-Custody certified since 2007 and an EPA Green Power Partner, the company promotes sustainable packaging practices through its DISCover Green program. DISC offers a range of advanced capabilities for prepress and design services, digital, flexo and offset printing, and finishing and converting for paperboard, plastic and mini-flute corrugate packaging.</font><br>
&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About APDN</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied, and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.adnas.com</font><font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;</font>where APDN&#160;routinely posts all press releases.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN&#8217;s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN&#8217;s SEC reports and filings, including our Annual Report on Form 10-K, filed on December 15, 2010 and our subsequent quarterly reports on Form 10-Q.&#160;&#160;APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">INVESTOR CONTACT: Debbie Bailey, 631-444-8090, fax: 631-444-8848</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">MEDIA CONTACT:&#160;&#160;Janice Meraglia, 631-444-6293, fax: 631-444-8848</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FCMN Contact: info@adnas.com</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Web site: <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.adnas.com</font></font><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>applied.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 applied.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!&`;`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B
MBB@`HHHH`****`"BN5G^.O@BV^(Z^#I?&7A6/Q<Q"C0VU:W&I$F/S0/LY?S,
MF,AQ\OW>>G-=50`4444`%%%%`!163XW\?:%\,_#DVL>)-:TGP_I%L566^U*\
MCM+:(LP50TDA"@EB`,GDD"G>#/'&B_$?PU;:UX=UC2]>T>]W?9[[3KJ.ZMI]
MKE&V21DJV'5E.#P5(Z@T`:E%%8>M?$_PUX;\36FB:CXAT2PUF_"&VL;B^BBN
M;C>Q5=D;,&;+*0,#DC'6JC"4G:*N3*26[L;E%%%24%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!16;XQ\9:1\//"FI:]K^J:?HFA
MZ/;/>7^H7]PEO:V4"*6>621R%1%4$EF(``K\,O\`@J+_`,'B&E:/!J_@[]EK
M2CJ]U+"L<?Q!UFU>&VMV906:TT^>,/(R[BH>Y"*'0_N9$PS`'[:_&;XY>#/V
M=/A]?>+/'OBG0/!WAG30OVG4]8OH[.UB+,%52[D#<S,JJHY9F``)(%?E#^V?
M_P`'DWP.^#.IVVG_``;\(:]\:IFPUQJ,\TOAK3(E*$XC-Q;O<R2*V`RM;QK@
MY$C=*_G>_:=_:R^)/[9WQ2N?&GQ2\9:WXU\2W2^7]KU"8%8(\DB*&)0(X(@2
M2(XE5`6)`&37U!_P2@_8K_9&_:8U?1Y/V@/VG)OAEJ-U>SP2>%$T*6R$\2QL
M8Y6UR8/96X+#)62/)`VA@S`@`VOVJ?\`@YL_;"_:C_M:S3XE?\*XT#5?)_XE
M?@FR326M/+*L#%>_/?H6906Q<X;++C82M?5?_!II^RU^T_HW[<!^)Z:=XP\,
M?!'6]+N9O%E[K<<MO9>-#)%<"S%L)ES=31W9\WSX_P#5HLRM*OG^7+^UG[#W
M_!*;]F/]BCR/$?P9^&?A/3+Z]3SK;Q")Y=8OBC1LA,%[<R321HZ,P*Q.J,&Y
M!KZ8H`****`"BBB@`HHHH`****`"BOQO_P""X'_!<SXS>$/VQ+;]DK]DW0+V
M_P#BU<>7;:SJD6DI?WL,TUO!>11:>K,T2A+9I&GFGC*QH6(,?E-(/F'XH_#W
M_@JQ_P`$C?"P^./B'XEZA\3/#&F#[7XATJY\1S^)[/38/XOM5I,$*1#<=TEH
MV$`R711F@#^BZBOF/_@DK_P4JT+_`(*D?L3Z+\5;"TM]#U..:72O$>E"8R+H
M^H0!3+'O(&4:-XYD//[N9`3N#`?D)\0O^"LO[9O_``7H_:?\2?#S]CXZA\-?
MA9X><-+K<9_LN\BMW4"*;4M0!D:!Y)(9C%#:;7*%U(E$;NH!_0O17\[5E_P4
M0_;N_P"#>SX[^&M*_:<N=0^,?PD\3SB,W]QJ3:P\R`[I6L=0DVS)<H&SY%U\
MKJN`%!$J_KQ_P4@_X*O^"/V#_P#@G;)\?;":R\7V/B&UL_\`A"[:*X\J/Q)<
M7L?F6NUB,B/R=\[\;A%$^!NP*`/JVBOYT_ACX(_X*L?\%?/")^-OA[XD7OPP
M\+:@3=^'M)M/$%QX6L]2AP,?9;:$,\L/RC;)=N0X.0[*2:^E_P#@B!_P7,^,
M_B7]L:?]DG]K/0;RQ^*T`DM=&U6;3$L;Z2>&WFO)(=0"L(G#VRQM!-#&%D4*
M29#*LA`/G?XM_P#*[M:?]AK2O_40MJ^U_P#@MM\;OV]_AS^V[\&M*_9;\+WN
MK>`+^T22^DM]&BOK"^U+[4RS6^JSOG[):+`+?:VZ#(FG*RED'E?%'Q;_`.5W
M:T_[#6E?^HA;5Z]_P<K_`+??QG_98_X*4_`7PK\.OB3XI\'>'/$6DV<VIZ?I
MEV88+UWU66)F<=R8P%^@H`_;^BOSQ_X."O\`@MO)_P`$C/@[X<T[PCI%AKWQ
M4^()G;14U!1+IVDVUO)`)[FYC25)6+"79"HPK.KLS$1&-_SET7]C_P#X+`^+
M_AROQP'Q0\966MRP_P!IQ^#+GQ*+74GCV\#^R#&+%&*?-]G?;)GY3&)/EH`_
MHHHK\W_^#?/_`(+?7_\`P5,\"^+/!_Q(TK3?#?QC^&P234XK?%M!K=F\CQ_:
MHK=W,L4D+JL=PN"BO+"P*^;Y4?PA\:?^"NG[8'_!<K]J[Q%\+_V,'U/P1\*]
M"E`D\26\#:5>&!D&VXU#4"7:U$DL,Y@BM_+E="P99"C;`#]`/^#J/_E"+\5?
M^OW0_P#T[V=:G_!KY_R@O^!W_<>_]2#4J_%__@J]J/[?O[!_[)>L?!7]H[7?
M^%C_``K^)=W:+9>*KJ\DUP6]U:SI>"&&^;9/'(YC&8[M3O2-S$/D=A^I?_!$
MS]JO2?V-?^#:_P"$OC;5(5OIK8ZW:Z=IXN$ADU*[D\0ZD(XE+=@-SL5#,L<<
MC!6VX.^%PU7$5HT*,>:4FDEW;T1E7KPHTY5:CLHJ[/U0//<BORY_X*>_\IF?
M@-_W+7_I\N*YWP):_MH?\%#]/;X@Z/XKF\%^&R3)IL5OJDVBV%V`=K+#%'OD
MF4,GWIR5R2%8\@>-7_Q0^)GQ)_X*4?"*V^+MM]F\<^$_$>@Z'>!X$AFD1=26
M='D$9\MF*W'#1@*R;"`<EF_4.&^%YX/$5:OMZ<Y0I5>>,97E&\&NUGJ[.S=C
MXG-\[6)HTX>RG%2G%IM63U_5:G[FT5\2?\%>_P#@HCXA_93L_#W@KX?RVJ>-
MO%$;7,UPT'VB?3K7=Y<1BC(*M++*&"E@P`B<;264CY:\>W_[9?\`P3\TW2?B
M1XF\3:QKFC7TB?VA97VK2ZQ96#OG;#=19VPAF8J&@8)NVC>"4!^8RO@W$XW#
MTZSJPINJVJ<9.TIM::*VU]+OK\CW<;Q!1P]65/DE)0MS-*ZC?NS]@**\)T#]
MOWP?=_L-P_'C4(=3L_#9M#--9I$);I9Q<FT^SH.`Q-P/+5B54@AF*KDCX/\`
M"WCO]K__`(*AW]_X@\(ZO/\`#WP="Q6R:UO9]'L6PY!6*XC4SW#J8\.P)4-D
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MXI?"6;[9%XDTEO&VJZY(5;3[D6SK'J%NH`6[-N<Q.&..05S6U_P7\_X+X>)/
MV!OB%X;^!_P)TC3?%?QM\5I$]R6MVU)M"6X;R[2WCM(SF6^G8ADC?.U/+)CD
M$R8\<]$_56OR_P#AA\9OVZK[_@X5USPCXDT?5X_V68A>>5<VN@Q+H,5@-,=[
M*6._DA622\:[,`E02.0[S*%\I%*^9_\`!+#]FK_@IJ?VS_A_X^_:&\>WR_#)
M7NI]?\/76O6?F2))8SI`#:6B^4"L[0MM!!4J21D$5F_\-T?&#_B+^_X4I_PL
M/Q/_`,*G_P"A6^U'^S?^1*^V_P"K_P"OG][_`+W-`'[/45^/G_!=O_@N5\5_
MA3^T_8_LI_LJ:+?:O\9=0BC37+^#13?WNFO/##=P0:>C$QM+]E+R32R1/'%%
M("I#J[1?*OQ1^$G_``5@_P""6'@23XZZS\3M5^(F@Z.IU#Q'HLGB.7Q/!I=L
M/]8US9S*%6$!CO>S8^4JLY:-4W@`_HMHKXU_X)U_\%D/!?[:_P#P3)U;]H;5
MH!H`\`:=?S>.=+M`]PVD7%A;FXN!$&P9$D@V2QC)XE"%BZMC\@OA;^TG_P`%
M'/\`@X4\<^,/&'P@\9S_``B^'_@ZX^SVUKI&N7/A_3(YF3<MDMU$IGO;KR]C
MR%SY:&16Q`LL:$`_I'HK\:/^#?G_`(+8_%KXD_M5>(?V4/VHC*?BEH8N;;0M
M0N+)8K^YNK/SY+VSO'C;RY'6%0\4B(%9+>0L[ED+6?\`@N)_P7D^,'PL_:\B
M_97_`&4_#=UJ_P`6&C2+6=131#JE[!/-;0WD,6G19:-F2V9WFDFB=$5C@*8V
M<`'['45^0W_!*;]D3_@I+X(_;9\%^,/VBOB9+J7PQMHKXZYH4OB:&[>1I+&=
M+=?(@0Q,5N'B;Y7P-F<G`!^>/VL/^"QW[5/_``6'_;0U[X(?L1R7V@_#[0+A
MX9?%FG)]CN=0C0$/>W-^Q86=H\D;^0(_+EE4C=N9_)0`_H`HK^=#QI^UK_P4
M4_X-Y?'_`(<UCXWZY/\`&[X4^(KH6T\U_J\^MV,T@P[P)J$J"YL[HQ[S&)1Y
M;[7(241.%^S/^"\O_!?&Z_9>_8!^$7BKX"7ZR:S^T3;37^@^(GMX9TT73K>*
MW>Y/EN65;T/=P1!'1Q&5GW`.B@@'ZQT5^#?P(_X)<?\`!4/P!=^&?B;I?[5=
MEX[LKA[74I]$3XCZCK*7]M(Z&2.)+R`Z>Y\MFY$@3Y?D<_*3^W_QG\$WOQ+^
M#WBSPWINK7.@ZCX@T:\TVUU.W8K-ITLT#QI.A'(9&8,".ZB@#^5K_@X*_P""
MY>M?\%._C9>>"_!.IW=E\"/"-\RZ-!&DUI+XFE"1*U[>1F1ED42I(;<,B,D4
M@+*LC,!RG_!,G]@#X1ZAKZ>*/VF+?XC3Z#%Y4UAX7\+Q00SWQ$C>8M]--+&\
M,955`2#]XPD)\V(IAOD[X:W$W[*'[6/AJZ^(7@>749/AYXJL[KQ#X1UNV^SM
M>K:72/<:?<1RHVT2*C1L'0C#'*GH?W_^"G_!8WX'?M%>'VU+P9^QY\,M=AB"
MF>*WALWGLR2P"S(NG$QDE6QG@XR"1@GZ;AC+:.,KRIU:4JMEHHSA!^MY;^B/
M%SK&5*$(NG-0N]W&4OEHM/G\CP/]KG]E#_@G9^TGJ#ZEX<\`?'3X1ZPT+*!X
M5735T^>3`"O):W%S*H"X^[`8=V3DY.:_,WXY_P#!-?7/!6O:A)X'U=O&?A^%
M_P#0Y+RT32]3N$VY+-;"6:)2#QA9W)X]<#]XA_P4)\`B6-'_`&&_`R&3H/L%
MON([X!TSFF)_P4.\`2;-O[#O@-O,SLQ96QW8ZX_XEG.*^RGPA1E%\F`J*^S]
MO2?Z:]?ZW^?CGE>,ES8F/I[.?EY>:^\_GO\`@-^TQ\=/^"=WCQ=9\!^*/'/P
MPU:=EEE2%Y+:WU`)O5?/MY!Y-PJ[GP)$=022!FOU$_8]_P"#S_XK>"M7L-/^
M-O@#POXXT&.-(9]4\/1OI>L9`.Z9XV=K:9CQ\B+`O7D<8^P-9_;M^%_BO3Q:
M:E^P?\.-2LY\GR;C2[2>.3'^RVF$'%?$/[:G[$7P*_:>O[O6O"G[./C?X+^(
M+M6V#PUK[MI$DQQAGL9M/8``#`CMW@!R3R>OS=?@3-N>U*CIVE.G?3?[?XZ?
M@>S1XDP;A>I/7RC.WE]D_2;X1?\`!V3^S'\9@8M-TGXG6-^76-+'4+#3K>XD
M+9P%'VTJ^<'[C,1QG&1GT@?\'"_P=)`'A3XFDGI_H5A_\EU_,1\5?^"9GQ=^
M&@^U6/A76_$E@"?WVEZ=<32QX&26C";@/==P&1DC->K_`/!-W_@M-KG[#^IQ
MZ1XV^&?PX^-W@:6;,]GXGT6WEUBS7:X_T2_>-G7YF0E)EF3;'M01Y+#BIPP&
M#D\/FN&GSKM.WX.+^].WD:SEBL2O;8"O'E?>-[?._P"#5S^B%?\`@X6^#;(#
M_P`(K\3BQZ`6-@0?_)RE/_!PG\'-@(\)_$\MW'V"PQ_Z65\@?`G_`(+0?`O]
MI70GO_!G['/PXU86X7[3;+!9-=69;=M$L::>VW.QL')!VG!.#7=)_P`%"_`,
MJJR_L.>`V5SA2+*V(;Z?\2SV/Y5]=A.&<'7I1K4L#4E&6J:KTK?EWO\`D>'6
MS;%4ZCI3Q$5):->SG_EYK[UW/OW]BG_@H;X*_;N/B)?"6G>)=,E\,"W-W'K%
MO#"S"?S=A3RI9`1^Z?.2#P.*]XK\M/AK_P`%A8/A#;W$/@[]E#3O"T6IL&F3
M1KH6*W14$`L(M/7<5!/)SC)K[`_X)^?MVZG^VYHWB.YU+X=ZMX%.@S0QQO<7
M#W-M?B17)$<C0Q9="GS*`=H>,Y^;%?+9]POC,)SXI4'3HIJW-.$FKV6O*]=>
MR_(]O*\ZH5U"A*IS5'?:,DGUZKM;K^9]%T445\F>Z?SB>!?B-H?_``2O_P"#
MM'X@ZY\;[BS@\.^--3U6\TWQ1JT<HM]%@UB(W-G<Q2.GW(]QT]Y%_=Q@S@L%
MC;'ZV?\`!2K_`(*U?L[_``#_`&'?'NMZCX]^&?Q!76/#MU:Z=X6LO$%EJ$WB
MG[1']G6%($D9I8&:91*R@A(B['.,'K?^"F/_``2`^#'_``5:\$Z?IOQ,TO4K
M36=%;.E^)-$GCM=7TY"P+PK))'(CPOCF.1'4$EE"O\P^)/A-_P`&9?[.?@GQ
M*VH>(_&_Q/\`&$$6_P`BPFN;2SM261E4R^5#YC[6*N`KH"4`8,I*D`^.O^#;
M3XAZOH/_``2(_P""@T-K>W,,?A_P;<:M8A)67[-<OHNJAI4Q]UC]FAY'/R+Z
M"NX_X,]O^"@_P;^`OPR^)_PL\=:_X0\!>,-9UR'7].U;6;R&P_X2"V-ND'V,
M3R;5+6[QLZQL^YOMLA13MD(^S](_X(R>`/\`@D!_P2N_;)M/`GB?QCXE3Q]\
M,]9EO3KTELYMS:Z1J(01^3%'C/VA\[L]%QCG/YF?\$`?^"$OP@_X*Y?L4>,]
M?\<:KXQ\,^*?"WC*73K/4]`NX4\^W:RM)!%/%-%(K*CF1E*;&S(V688``/JC
M_@[J_P""C_P=\?\`[&_AOX.^%/$GA+X@^,]7\3Q:O,VD:E;:BOA>*TB<-)*T
M4C-#<2_:5C12OS1M<$D84-\R?\%W/A+XU_9/_P""'?[#/PK\976HC6;9-0U+
M5K.Z9EEL9S%'-%:2*>CVL=\]OC^'RR!Q7Z8?L$?\&K?[.?[$GQ;TKQYJ-UXG
M^*?B71&,MA%XF^ROI-G/R%G6T2(!Y%!RIE>0(P5U"NJLORS_`,'OO_)+OV=_
M^PKKG_HFQH`^_P#_`()A_P#!6K]G;XX_L'_#K5++X@_#7P!)H7ANST_4_#&H
M:_9:=-X9>VB%NT)ADD5DMP86\IR`'C"L,<@?D[\5_B+H/_!57_@[+^&NJ_!"
M33+G0/`FJZ1<ZIXHTI9&MM=AT;_3+R[DE1.5<*-/CD),<@2W`<I(M?2F@_\`
M!H'^SW^T%\./!?C72O&7Q+\%2>)M#T[4[_2[.YM;NRCDEM(FD$'G0F6,,Y9L
M/)(`6(`"@*/T#_X)F_\`!'[X+_\`!*3P9J.G_#/2M1O-;ULXU3Q+KDT=UK&H
M1AMRPM(D<:)$IQB.)$4[0S!F^8@'Y"_%O_E=VM/^PUI7_J(6U)_P=J_\I:?V
M:_\`L"6'_IYFK]1O$W_!#3X<^*/^"L47[7DWBSQK'XZANK:[&CH]K_9):'3$
MTY1CR?-P8HPQ_>?>/IQ1_P`%(O\`@AE\./\`@II^TCX#^)OC#Q9XWT+6/`%K
M#:6=KH\EJMM<+'=-<@R"6%VR68@[6''OS0!^4'_!Z=\#=?T?]LCX._$^<S)X
M/UOPI_PC,=Q;JTDEG>6=]<7,I8?*BEXKZ(QC>"YAEZ!,TW2?^"9*Z]\)(_'-
MI_P5IT0^&I+=;G[5/XANK=HPRAA&\3ZH)8YL$#R602!CM*AN*_?+]J_]DCX>
M?MO?!/4_A[\3_#-CXI\+:J5=[:?<DEO*N=D\,JD/%*N3AT(8!F&<,0?RT/\`
MP95?L^_\)091\4OC(-#/_+IY^F_:NG_/?[)L_P#(5`'D'_!N%^QI\)_BM=?M
M,:_\,_C5\0_'OQ-\1>"KKPI>>)+_`,./H=MHO]K,\BW&Y[B>:XNGGM%E$F5V
MB)\@EP:X7_@T=_;4^&G[%GCKXX?"KXO:OHGPL\9:Y?V$EK-XF<:2]Q+9FZAN
M+">2?8L4T,D@VQ2$.6FF`&5(K]U/V,/V)/AI_P`$_P#X&V'P\^%?AJU\.>'K
M.1KB8K^\N]2N'QON;F9OGFF8!5W,3M5$10J(BK\K?\%,/^#;_P"`'_!3+XI/
MX^UE_$W@+QW<P^5?:IX9FMXH]9(VA)+N&6)UDD15*AT,;D$!V<*@4`^8?^#K
MW_@IE\$]:_8!G^#>@>(O"/Q"\=^--6M)X$T?4K746\*I9SQ3R74QC9S!)(A\
MA%.UG2>8@E58%WC3]BSQE^S;_P`&\G[.OAW6M.N[34/!DPUGQ#831/!+I)U2
M6ZN52>.0*R2Q2WL<#H5RLCL.@)KV']AO_@U$_9O_`&/?BGIOC36[GQ-\6=:T
MG<UK9^*%M)-&BD(($ILTA'F.H)V^:[J&PP4,JD?I?XA\/:?XNT*\TO5;&SU/
M3-1A:WNK2ZA6:"YB889'1@592"000017JY'FCR['TL<H\W)).W==5\T<.9X)
M8O"SP[=N9;^>Z_$^9O\`@G?^VM\,/%_['W@2T;Q9X<\/ZEX<T6UTB_TO4=1@
MM;BTEMXEA)"/(6,3F,LC$DLI&<,&4?'WQM\::+^VW_P6N^')^']W97]AX;N=
M-^TZI&P>UO\`[!/)?SRHZ`[EV?N58\,Z*`=I5C[GXY_X-^/A5KWB"6[T3Q)X
MR\/V<SEOL(GANHH!V6-I(_,QU/SLQ]Z^@_V//^">WPW_`&)+*Z;PC87=YK-\
MABN=:U1TGU"6(L&\D.J(J1Y5?E15#%%+;B`:^N68Y%@'6QN7SJ3JU(SC&,HI
M*'.K-MI^]9-VMUW/G_J>98E4\-B81C"#BVT[N7+V72_R/BC_`(*@(LO_``66
M^!"LH96'AL$$9!']N7'%?4G_``6>_P"4;WQ!_P"NFE_^G2TKHOC[_P`$ZO"7
M[0W[47@_XKZMK/B*SUSP9]@^R6EI)"MI-]DNWNH_,#1LYR\A!PPX`Q@\UZ!^
MU)^SGI/[5_P+UGP#KE]J6GZ7K9MS-<6+(+A/)N(YUVEU9>6B4'*G@GOS7G3S
MK#.>6R3=J"7/IM:HY:=]&=<<NKJ&,5OXE^77>\;?+7N?GW;>%;[Q5_P;HVPL
M(;^YETZ:>^EAM59R\,>ORM*SJH.8XTW2L>BB/<2`#7LG_!'']K'X<P?L6>&?
M!U[XJ\.Z'XC\,O>QWEC?7R6LK^9=S3+,@E8%U*3)EERH8L.,`5]/?LP?LX:-
M^RK\"-&^'NC7FH:GI.C?:#'-J!C:>837$D[AMBJI`:4CA1QC.:^7_C#_`,$$
MOA+\1_&FH:SHVK>)_"*:G<&=].L6MY+"UR!N6"-X]T:ELG;O*KG"A5`4=LLZ
MRS&TL3@L;*4(2K2JPFE?>ZM);ZJUM=&<T<NQN&G1Q6'BI25-0E%NVUMGMN?*
MG_!=3]J/P'^T+\2_!^D>"]4L_$$GA*TNCJ&JV$D<]E.;@6[QQ1S*2)2@C8MM
MRJF3&=P=5^BO^"U'_!,O]GC_`(*D^*O!?@SX@?$[3/AK\8M)LIYO"KPZA91Z
MCJ-K,X#H]I,5DO(%>%B%C93&Y8A@'8/M:G_P;]_!V\T"PLX==\=6US;-*UQ?
M"]MWFO-^W:K*8?+54PVW8JD[SN+<89_P5Q_X(&_#C_@KMXQT#Q1XJ\9>-_"?
MB;PQI1TBPDTIK:6Q,1E:4M+!)$7=MSGE94&,<'K7'Q/F&65<'@\'ELI25%33
M<E9N\D[]M7=I7=E9,ZLEPF,IXBOB,7%)U.6UG=:)Z?+1>;/R2^&^L_M*?\&]
M_P#P5@^"_P`&KSXTCXK>!_%VI:?92>%++5;N^M1IU]=BT93ILKC['>C<983&
M2K,L>6D4R1UV?_!3;QE;?\$T?^#K/P[^T#\6O#6HW'PK\1?8]3TZ]@LQ=)*B
M:!'I,DR!AM:6TNPLS1J3(JB)@,O'G[R_X)Q_\&MWP4_8(^/FB?%'5/$WBGXH
M^-/#4C7&E?VS#;PZ98W&,)="V569IX^L;/*P1L.JAT1E^P?V^_\`@G'\)?\`
M@I7\'9/!OQ4\-0:I#"K_`-F:M;JD6KZ#(Y0M)9W!5C$6,<>Y<%)`BAU8#%?&
M'T1N_"?]O+X'?'C7K'2?!'QC^%GB_5M3W?9+#1O%5C?7=P51G8+%'*SDJBLQ
M&,@*Q.,&OQ@_YWH/\_\`1/Z^ROV&?^#7;X)?\$__`-KOPC\8?!WCGXJ:GK'@
MV2ZDM+'6;NPFMIO/M)K9A(8K6-CA)F(P1R!VR*]C_P"'*GP^_P"'N?\`PV-_
MPE/C+_A/?^@-YEM_9'_(%_LCIY7G?ZGY_P#6??\`]GY:`/P?_P""R?P@U/P-
M_P`'(7C*V\5?$[Q%\&--\9ZA::AIGQ">TN5%A:7.EQQ)+$T;Q.]LDPDLGEC?
M:@BESGRV6O3?VHO^"<ME\!?V?]1\5^+/^"I5IXD\.7=MY1TS1]4N-:NM;BE9
M8FCM[6/56:Y7]Z-X`*JA9F(4$U^YO_!2;_@E3\(/^"J?PJL_#'Q1TF]6ZT>7
MSM(U_2)8[;6=&+,IE6"9XY%V2!`KQR(Z-A6VAT1E^"_AI_P9?_LZ^%O&D>H>
M(O'OQ5\5:5;RI)'I9NK.RCG`(+1S21P>8R-R/W9B8`\,#S0!P7[#?[.WPM^!
MO_!LA^TWK?PJ\0^-_%UGXST#7I=0\0Z_H+Z$FJRP69@Q96Q=_P#18_GB+^9(
M6F2X!8;1&GI__!F%&L?_``2O\9LH`+_$_46;W/\`9>E#^0%?HK\7/V*?`WQ*
M_8Q\2_`C2]-M_`_@/Q#H%SX=2U\.VL-FNF6\ZLKF"/88U;+,W*D%B20237$_
M\$M_^"8_@[_@E!^SSJGPW\#Z[XF\0Z1JNOS^(9+G7)('N4FE@MX"@,,<:[`M
MLA&5SEFYQ@``_)F&!+?_`(/G2L:)&I8L0H`!)\`$D_4DDGW->9Z5\3M%_P""
M5?\`P=H^.?$WQMF@C\->*M6U*]L?$M_!,T.D6VL6QEM+F)F3)2+S/L,CK\D8
M%P-VV,BOU[_X<J?#[_A[G_PV-_PE/C+_`(3W_H#>9;?V1_R!?[(Z>5YW^I^?
M_6??_P!GY:Z[_@I5_P`$C/@O_P`%5O`NGZ3\4-'OX=5T5LZ5XCT6=+36-,4L
M"\<<KI(C1OC!CE1TR=P`8!@`>E_##]MOX+_'/Q!::-X)^+_PP\7:OJ(<VMGH
M?BFPU"YN`B%W,<<4K,VU%9C@'`4D\"OY,_\`@F;^S5J>M?M+>-/A1XM_:1U;
M]C[Q39MY$YU1I].M-2NK9Y$DL[F5;JW6*>,N3&LF0^^0*0VU9/WV_8!_X-B/
M@S_P3J_:Z\+_`!A\'>.?B=J^M^%%O%MK+6;FQEM91<VDUJV_RK:-LA)F(PPY
M`[9![K_@IY_P;S_`3_@J/\08?&WB9/$/@OQXL(@N]=\,2V\$NLJJ)'$+U)8I
M%F,:($5QLDVA5+E415`/Q6_;^_89\$_LZZ'IOA_XJ_\`!234/B'8Z]/^\T+0
M[&Z\5R0"(+();BW75&CB7+1[#*5+DDH"$<K^L/Q<_P""8?[(/C[_`():_`O]
MG_XB^)[OX<Z3]A.I^`-2\5ZC::'XOAN9F6ZNPJW2X$LK70\^T*'&]1L1XHVC
MS?V+?^#2[]FW]E3XH:;XP\17OBCXM:CI19H-,\3)9OH;.00'DM%A_>E<Y"R2
M,F<$J2!CZ*_X*S?\$9OAS_P5^\-^#K+QYXB\9^'+CP')>2Z5/H,]LBLUT(!*
M)EFADW@"W3`4H02<D]*`/PJ_;5^`/[1W_!K_`/%OX=:G\/OVB#XD\'>);RYO
M=*T.&[N;>TOE@\LRKJ&D-(T#Q2"XVB1'9MVY@T3A&K^HK2[XZGIEM<F">V-Q
M$LODSKMEBW`':PYPPS@C/6OR2_92_P"#/3X%?!#XLZ1XK\=^-?&'Q7CT*Z2[
MMM#O[:VL])NRF2L=W$!(\\8;:WEB1%;;APZ,R']=*`/S>_X+;_\`!NWX%_X*
MG1W7COPM=VG@/XW6]H((]6,873?$>P1K&FIJD;2LR11^7'/'\Z*0&654C1?Y
MUOBK\#OVH?\`@B)^T67OH_'/PE\2PS/;6.O:7-+%INO1IY<C""Y3]S=PD-&7
MC.X#<%D16!4?VE5S/Q>^"W@[]H'P+=>%_'?A7P[XS\-WS(\^EZWIT-_9RLC!
MD8Q2JREE8`J<9!`(P:`/YR?@[_P>/_&^TL[:R\:^%?A[=21HJ'4;'1I1)*1P
M7DC-RJY/!.S`ZX7H*^W?V9?^"UOQ]_;'@@/PPTOX/^-+J>%I_P"S]/DB.I1(
MK,I:2T:^%Q$,J?OQKD<C@@UR?[>G_!FI\-OB3;:GK?[/_C'4OA[K\[F:'0/$
M$K:AH)^50(HYE4W5NN0S%G-SRV`H&`/R5_:J_P""$'[77[`GCA+FX^&_BGQ!
M;6#&>U\3^`X[C5[--BJQE\R!!/;;2V,SQQ$D'&0,U[N79U##1Y:F&IU/.4=?
MP:3^:OYGDXS*I5I<\*TX>2EI]SV^6GD?OM!^T[^WC(8@OP7\*_,"039<?B3?
M?SH'[47[>,1"'X+>%CM)!_XE^[]?MO-?SN_#[_@MK^U;\.%6V;XZ_%'6;2(L
M#;:MXFO[@Y.1S)YPE&/3?CVKW_X+_P#!??XA^);^UT_Q?\4_BCX7,\JQMJ,?
MBG4[FR@4]9)$C=IE`XX1)">?I7T66YAEN)LJM.C3?]Z,[??&^]OQ^[Q,9E^,
MH_PZE6?I)?D['[3M^U!^W?!A9/@KX6+'GY+$,/S%[7P9_P`%'O\`@D!\;/\`
M@HGK;^*;K]GO0/`?C=/,DGU;PQ8P:>=9D<@@WL?VAEF;.?W@42?-RS``5[9^
MS/X/^,/[9-O"WPN_;4\$>-KJ:#[4=/T[XJZPVI0Q9(W2V;1"XA&0?]9&I[].
M:^(O^"BO_!5KXE_LA^*9O!_A#]I;4/B7XI$:FYU+PIXYU/4])TLE0=K7#%(Y
MI@I`VQ%U0DAR&0QGU,94RF.&DE+#2LOLQJ*3]'9:_-')1I8]U%;VR]91M\_+
MY'P;^R;^UE\5/^"3?[9/_"4>%+D:-XQ\&7USH^LZ7=.9;'4%1VAN+*[CC<+-
M'O4G&?E>-)%(9$8?TIV?[4G[=VH6\#P_!KPF\4B"1&^QC:P(Z@F^YS_+FOYT
M/^"7'_!+WXF_\%9?VCI/"_@^T<Z7IJ_;_$_B._=X[#2(FWE!-.$D/GSLC)&@
M5W8[WV[(Y63^@I/^"8/[9UJ@"?'[/;Y?'NNC_P!H"OF>&(X3]Y];E26UO:*;
M[[<J?SO^A[>>*NW#V*J/>_(TNV]_P.C3]J3]O!54?\*5\+X[_P#$N)/_`*6U
M-%^U;^WA&@`^"_AM2>NW3\#_`-+:Y?\`X=F?MH_]%]D_\+_7/_C-'_#LS]M'
M_HOLG_A?ZY_\9KZVE_9$'?VF%?K&J^W]W^KGSSIYAVK_`/@43Z#_`&+?C=^U
M?\1OC-%9?%7X=>%O#/@J.VEDN[Y8VM[E9-I\I(0+B7>2^-P90H4,=P;:K?7]
M?EY_P[+_`&T<D_\`"_'R?^I_US_XS6IX*_X)O_MFZ-XPTN[G_:#^S6]O=1O-
M*_BW5M2$:;OF;[--"(IB!DB-R%8C!(!R/G\TRC+J\W6I8NA#3X8JHE^,7J>Q
M@<?C*%-4YT*D_.3C<_2^BBBOA3ZH\I_;P^%6M?';]AWXS>!_#=O%=>(O&7@7
M6]#TN&2584FNKK3YX(49V(509'4%B0!G)KXR_P"#9G_@G'\5_P#@FK^R=X]\
M*_%O1;#0];U[Q:VJV<-KJ4%\LEO]CMXMQ:)F4'?&W!.>*_2.B@`K\L/^#GS_
M`():_&/_`(*<>`O@_8_"'0].URZ\'ZAJD^I)=ZI;V`B2>.V6,@RLN[)B;@9Q
M7ZGT4`<=^SOX0O\`X??L_P#@70-4B6#4]#\/6&GW<:N'6.:*VCC=0PX(#*1D
M<&NQHHH`****`"BBB@`HHHH`*\_^,_Q=F^&GC'X>V$<$TT'BK79=.NC'937+
MK$FFWMR"GE@X8R01CY@?E+\<;E]`KB?B_P"&Y-0U?P=K8\XVWA'69-4NXX8G
MFEGB;3[RUVK&@)<AKE6VXR=O&2`#I24>;WE=:^733\2*CDH^[N9Z_'SP]X5U
M;QTNJZC>+!X5N89M2E%G<3P:7%);0N`[HK*NU3YCC(,:.LCA48.W5:Q\1-+T
M3Q-8Z-*U[-J6H))+'%;64UP$1.K2,BE8@3PID*[B"%R014?A;2&TZ_\`$\S0
MB$7^H"97*%3*HM8$W$XRW*$9YZ8[8KS#5]-OOA;XRUSQ#JE]XGBTG7K:P\N7
M0]*;5;R-XH?*>U>".VFF$2D&59%)0M<S`JA`:7HC3IS;MT2Z[O3;3U[O\SFJ
M5*L;**O=OILM?/TZKOY'K7@_QG8>.M(-[I[7'EK(\+QW%M+:SQ.IP5>*55=#
MT(W*,@@C(()GM?$MC>^([W2(I]VHZ?!#<W$6QAY<<S2+&VXC!R89.`21MYQD
M9X_X/^$[NP\2>(]?N9+YXM=-JMLUX/*N+B.*(XFFA$40BE+2&/:4+[(8RS](
MX\G7/%`^$OQWU_6=6L-:FT;Q'INE6-C/IFE7>J.;J*2_,R2);12-"BI)`1))
MM4F0C/%92H^\XQZ?\#TVZZ=#2%9\L925KNWYV[[^O4AU[XGBX_:$\&3V-[J,
M^A77A;Q!++;V\4TBS30W^CPJ[0J,LT9DE4-M)4.^#AB3U>D>.CXDUC03!>O:
M1W,,YGL[C2YXYKIE2,[HW?:%5"XZJV_<,$;37`?#7P3KME\1/AE>ZGH]SITT
M7@S7AJ,3,DRZ7=W=[I$XM7E0E&==LR@J2&\ER.*Z3PIJ5WXH\0^#;JXT?5M,
MN-.TVX@U&WNH2/L,[PVC^5YJYBDP25$D;LC,CA6)4XUG"FXI)[)_^W?\`SE6
MFN5VWM=6>[<?R3>GZ(GL?VJ/`VJ7.@16VKRW#>*_-.AF.QN&765C<*[VYV8E
M0*?-#(2IAS,"8@7K8_X71H#^!D\1)+J$NG/</:!$TRZ:\:9)7B>,6PC\\NKH
MX*A,@*S?=!-<#X,\$:A;>`/V>X+C2KI+CP]]G-^CVY#Z>1H%Y`QD&/D_>.L9
MSCYG`ZG%=)X]T#4-.^)&@^+(X)K_`$S0%OXKRQ1&:1!/'#MO8D56:66+RGB"
M*`QCNYRI)`CDF<*/-RQOUUNO/R6^@J=2NX.32OI;1Z72OUUM=]NQT-I\5-)O
M=9U73%_M&/4='@2YG@DT^=&DC8'#Q90"<#&#Y1;:<`X)Q7$_`G]INS\:_L]?
M#WQ/XB,EEK'B[2=.E:W@T^YQ=7MQ:K.\=M'M9Y5`$C97<%2-F9MJLPIZMXXN
M_B5\7OAIJ^@:!JXT6UU"_MM1U*_TR[TR[A1["X*P?9[B%)/(>2.-GD?:OF1V
MX42$G9Q_PM\(:S\+/AW\,K"_T_Q!;3_#;PJ?"^MWFDZ<+JYMV6WM"LELA@D:
MZMI39\BW+2J[P!H^'\K2-&G:SNF_-7^UIMULNE]?-$NK7YF[:*ZVW^&SU?2[
MZVT9[UX9^(^D>+=?U;2;.XF&J:&8_MMI<6TMO-$L@)CD"R*I>-]KA9$RA:.1
M0VY&`=XL^(.E>";O3+;4)YEN=8N/LMG#!;2W$LS[68X2-6;:%5B6(PH')%<'
M\,--;QM\2K+Q1#+XLN-,TW1Y[*UN-<T_^S6F:>XB,D:VS+#,AC^QH2T\&")D
M\IR#*#<\8>&[^^_:U\#:G%9W3Z99^$?$5I<7:QDPP2S7>BM%&S=`SK#*5!ZB
M)_0UG.E!3Y;VT;]'9Z?/3II>VZ-H5IN',XZWM^-K]=O4UM0_:"\*Z;H.H:M+
M?W!T?2;MK*\U%+*>2SMY%?9(6F5"@CB?<LDF?+B*.'9-C[=34_B=I&E>,;70
M&ENKC5KJW:Z$%K9S7(AB!(#RO&I2(,0P3S"N\HX7<4;'CWA'Q#?^`O".F>%!
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M7P7KL:NEIX+\27>L7D*PR33SP/I]_:`1(BEF;?=1M@`DJK8R<5FJ5.,[2U5N
M_>-[775.R]=RW.;7,M/EV>^^S6N^QVOA_P`:Z;XIU+6;*QN&FNO#]VECJ$9B
M=#;3/;PW*IE@`W[FXB;*DCYL9R"`G@/QOIGQ,\#Z-XDT2Y-YHVOV4.HV$YC:
M,SP31B2-]K`,N58'#`$9P0#D5YOHWB(?!7XN^,O[6TWQ#=6_C_6+74]*N].T
MBYO[<D:?96+PS/"C"W97M0Y>81QE)U*NVR4):_89;SOV*/A`3AE;P5HX]L?8
M8145*"C3]HO[MOFFW]ST\NIJJMZBAY-_<TCI;GXL:3KMSJ^E:;)J%S=62212
M7$6GW!M%D5&+*MSL$+,I4JP5R58;3AOEJ/PC\=_#'BT>'H[+4'9/$\4LFDS2
MVTT,.I")=Q$4CH%<LF9$`.9(T>1`R(S#E?@VUW\*?@WX9^'>LVFKW&O:5I!T
MB.[BL;BY@U!;:)HUNY)T5XX6G2,2^7))N#2;,LW)[;QAHIO]6\'NMKYILM4,
MQ<1Y^SC[#<IOSCY?O!<_[6.^*=2-*-X[V;LTUVTZ;/\`SZF-.=5OG?6VEGWV
MWW773[D5M3^._AO2M/UF\DGU&6QT"X^RWUU;Z9<SP1.&"OB1(RKK&Q(D="RQ
M%)`Y0QN%O>,?BEH_@C4--L[U]1>[U??]FBLM-N+V1E0`LY$,;[$7<H+OA064
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M6Y$94QR,Q3<'7=L`!^I_[;W_``3+_97_`&DO!WB'7?C-\-/AM%%+$L^J^*[B
M&'1M0@2,KM>34XS',BC"CYI=I'RG()!_E_\`^"I_[+G['_[/GB2_3]GG]H/Q
M7\3KL7+6ZZ')X9\^TL"CJ)&DU@O;Q31LI<QFVMI@=F&<`AZX*VA_:D_X+.?'
M)8D/Q*^.7BV-PN6>2YM-&65B1DDBVL8696ZF*/(/I7Z#_L0_\&:?Q>^+.G1:
MO\<?&>D?".V\U"-#TZ.+7M6EC$CB19)8IA:P%D561TDN/]9\R*5*D`_&JQO;
MBPN!+;3302A6&^)BK`$$,,CL02#[$U^I7_!+;_@U:^-7[:.H6?B3XMV^J?!/
MX<R(ES&^H6B-K^LKYI5HH;-V#VORHW[VY5<;XV2.92<?O7^P-_P1&_9O_P""
M;][!JWP[\`6LWB^*!(6\4ZY,VIZPQ574NDDG[NV9Q(X?[+'"KC`92%&/K*@#
MS;]E#]D+X<?L/_!O3_`7PN\*Z9X3\-6'SF&U3,MY*5"M/<2MEYIF"J#)(68A
M0,X``])HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\_P#$OPO\4KXE
MUB^\,>+[71(M?:.2ZAO=);4#;R*B1-);GSXQ&S1(HPZR('4/MY=7Z[P7X0T[
MX>^#])T#1[5++2=$LX;"RMT)*P0Q($1`222`J@<DGBBBK<VURD1IQ3YEO_7W
M&E1114%A1110`4444`-$A.<#H,T"0G&0!GWHHJ[:$.3YK#J\1_:,_P"";7P&
M_:Z^*_ASQQ\3?A3X.\<>*/"L#VMA>:M8BX!@8L?)GC/[NYB5F=D2=9%1G=E"
MLS$E%06>QZ!H%AX4T2TTS2[&STW3;")8+:TM85A@MXU&%1$4!54`8````JW1
D10`4444`%%%%`!3/.XR1@9Q110`OF':&`!!QWYYIU%%`'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
